New MS Guidelines, Zyn's FDA Claim and Norovirus Warnings

Health expert discusses nicotine pouch risks following FDA marketing ruling

Following the U.S. Food and Drug Administration’s recent authorization for Swedish Match USA, Inc. to market ZYN nicotine pouches with a modified risk claim, a local tobacco treatment specialist is warning that the products still have their drawbacks.

New MS guidelines, Zyn's FDA claim and norovirus warnings

Earlier MS diagnosis is now possible, Zyn nicotine pouches get an FDA risk claim, and norovirus concerns rise with summer travel.

Philip Morris claims FDA nod to market ZYN nicotine pouch as safer than smoking

The FDA has authorized Philip Morris International's ZYN nicotine pouches for reduced-risk marketing. This marks the first such approval for a nicotine pouch product in the United States. The regulator concluded ZYN could significantly reduce harm compared to cigarette smoking. This decision allows adult nicotine users access to science-based health information. The authorization applies to specific marketing claims and authorized ZYN products.

The FDA Is Finally Following Its Own Science on Harm Reduction

Now that Marty Makary has departed as Food and Drug Administration (FDA) Commissioner, the agency he left behind is turning the page on his disappointing legacy. In May, while Makary was still in post, the FDA authorized four vaping products from Glas Inc.—including the first fruit flavors, mango and blueberry, ever to clear its review […]